Literature DB >> 28449533

Can mathematics replace anatomy to establish recommendations in lung cancer surgery?

Marc Riquet1, Ciprian Pricopi1, Antoine Legras1, Alex Arame1, Alain Badia1, Françoise Le Pimpec Barthes1.   

Abstract

The greater the number of lymph node (LN) sampled (NLNsS) during lung cancer surgery, the lower the risk of underestimating the pN-status and the better the outcome of the pN0-patients due to stage-migration. Thus, regarding LN sampling "to be or not to be", number is the question. Recent studies advocate removing 10 LNs. The most suitable NLNsS is unfortunately impossible to establish by mathematics. A too high NLNsS variability exists, based on anatomy, surgery and pathology. The methodology may vary according to Inter-institutional differences in the surgical approach regarding LN inspection and number sampling. The NLNsS increases with the type of resection: sublobar, lobectomy or pneumonectomy. Concerning pathology, one LN may be divided into several pieces, leading to number overestimation. The pathological examination is limited by the number of slices analyzed by LN. The examined LNs can arbitrarily depend on the probability of detecting nodal metastasis. In fact, the only way to ensure the best NLNsS and the best pN-staging is to remove all LNs from the ipsilateral mediastinal and hilar LN-stations as they are discovered by thoroughly dissecting their anatomical locations. In doing so, a deliberate lack of harvest of LNs is unlikely, number turns out not to be the question anymore and a low NLNsS no longer means incomplete surgery. This prevents from judging as incomplete a complete LN dissection in a patient with a small NLNsS and from considering as complete a true incomplete one in a patient with a great NLNsS. Precise information describing the course of the operation and furnished in the surgeon's reports is also advisable to further improve the quality of LN-dissection, which ultimately might be beneficial in the long-term to patients. However, that procedure is of limited interest in pN-staging if LNs are not thoroughly examined and also described by the pathologist.

Entities:  

Keywords:  Lung cancer; TNM; lymph node number (LN number); lymphadenectomy

Year:  2017        PMID: 28449533      PMCID: PMC5394034          DOI: 10.21037/jtd.2017.03.46

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  33 in total

1.  Value of the metastatic lymph node ratio for predicting the prognosis of non-small-cell lung cancer patients.

Authors:  Chang-Li Wang; Yue Li; Dong-Sheng Yue; Lian-Min Zhang; Zhen-Fa Zhang; Bing-Sheng Sun
Journal:  World J Surg       Date:  2012-02       Impact factor: 3.352

2.  Quality of Lymphadenectomy in Lung Cancer.

Authors:  Françoise Le Pimpec-Barthes; Marc Riquet
Journal:  Ann Thorac Surg       Date:  2015-08       Impact factor: 4.330

3.  Tertiary lymphoid organs in lymphatic malformations.

Authors:  Andrew L Kirsh; Sharon L Cushing; Eunice Y Chen; Stephen M Schwartz; Jonathan A Perkins
Journal:  Lymphat Res Biol       Date:  2011       Impact factor: 2.589

Review 4.  Tertiary lymphoid structures, drivers of the anti-tumor responses in human cancers.

Authors:  Marie-Caroline Dieu-Nosjean; Nicolas A Giraldo; Hélène Kaplon; Claire Germain; Wolf Herman Fridman; Catherine Sautès-Fridman
Journal:  Immunol Rev       Date:  2016-05       Impact factor: 12.988

5.  Postoperative survival and the number of lymph nodes sampled during resection of node-negative non-small cell lung cancer.

Authors:  Michelle S Ludwig; Michael Goodman; Daniel L Miller; Peter A S Johnstone
Journal:  Chest       Date:  2005-09       Impact factor: 9.410

6.  Randomized trial of mediastinal lymph node sampling versus complete lymphadenectomy during pulmonary resection in the patient with N0 or N1 (less than hilar) non-small cell carcinoma: results of the American College of Surgery Oncology Group Z0030 Trial.

Authors:  Gail E Darling; Mark S Allen; Paul A Decker; Karla Ballman; Richard A Malthaner; Richard I Inculet; David R Jones; Robert J McKenna; Rodney J Landreneau; Valerie W Rusch; Joe B Putnam
Journal:  J Thorac Cardiovasc Surg       Date:  2011-03       Impact factor: 5.209

Review 7.  Lymphoid neogenesis in chronic inflammatory diseases.

Authors:  Francesca Aloisi; Ricardo Pujol-Borrell
Journal:  Nat Rev Immunol       Date:  2006-03       Impact factor: 53.106

8.  Missed Intrapulmonary Lymph Node Metastasis and Survival After Resection of Non-Small Cell Lung Cancer.

Authors:  Matthew P Smeltzer; Nicholas Faris; Xinhua Yu; Robert A Ramirez; Laura E M Ramirez; Christopher G Wang; Courtney Adair; Allen Berry; Raymond U Osarogiagbon
Journal:  Ann Thorac Surg       Date:  2016-06-03       Impact factor: 4.330

9.  Survival Implications of Variation in the Thoroughness of Pathologic Lymph Node Examination in American College of Surgeons Oncology Group Z0030 (Alliance).

Authors:  Raymond U Osarogiagbon; Paul A Decker; Karla Ballman; Dennis Wigle; Mark S Allen; Gail E Darling
Journal:  Ann Thorac Surg       Date:  2016-06-02       Impact factor: 4.330

10.  Sublobar resection is equivalent to lobectomy for T1a non-small cell lung cancer in the elderly: a Surveillance, Epidemiology, and End Results database analysis.

Authors:  Syed S Razi; Mohan M John; Sandeep Sainathan; Christos Stavropoulos
Journal:  J Surg Res       Date:  2015-09-03       Impact factor: 2.192

View more
  1 in total

1.  Occult pN2 disease in lung cancer patients: a wide range of diseases endangering the long term prognosis.

Authors:  Marc Riquet; Ciprian Pricopi; Giuseppe Mangiameli; Alex Arame; Alain Badia; Françoise Le Pimpec Barthes
Journal:  J Thorac Dis       Date:  2017-08       Impact factor: 2.895

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.